Dr. Toby Maher reviews the FIBRONEER-PPF clinical trial of nerandomilast (now called JASCAYD) for people living with progressive pulmonary fibrosis from causes other than idiopathic pulmonary fibrosis (IPF). He explains how repeated microscopic injury can trigger an abnormal healing response that leads to lung scarring, and why targeting the PDE4 pathway may help reduce fibrotic activity.
Dr. Maher walks through the trial design, who was eligible, and the primary outcome (change in FVC at 52 weeks), with follow-up out to about 76 weeks. He highlights that nerandomilast slowed FVC decline versus placebo, appeared to reduce acute exacerbations and hospitalizations, and showed signals suggesting fewer deaths during the study period. He also reviews tolerability, including diarrhea rates, and discusses how this information can support personalized conversations with your medical team.
1. Pulmonary fibrosis in plain terms: scarring and abnormal repair – 4:28
2. Why PDE4 matters and how JASCAYD is designed – 8:36
3. FIBRONEER-PPF trial design and what was measured – 12:24
4. Who participated: eligibility and baseline characteristics – 15:18
5. Primary result: FVC change at 52 weeks and longer follow-up – 19:36
6. Background therapy: results with and without nintedanib – 21:57
7. Safety and side effects: what participants reported – 27:09
This video is for informational purposes only and is not a substitute for professional medical advice. Always consult your doctor for medical concerns. No personal recording or redistribution without PF Warriors written permission.

